Smith & Nephew plc (LON:SN) has been assigned a consensus rating of “Hold” from the eleven analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is GBX 1,317.30 ($17.73).
A number of brokerages recently issued reports on SN. Berenberg Bank reiterated a “hold” rating and set a GBX 1,340 ($18.03) target price on shares of Smith & Nephew in a research report on Friday, November 3rd. J P Morgan Chase & Co dropped their target price on shares of Smith & Nephew from GBX 1,382 ($18.60) to GBX 1,369 ($18.43) and set a “neutral” rating for the company in a research report on Monday, November 13th. Jefferies Group reiterated a “buy” rating and set a GBX 1,515 ($20.39) target price on shares of Smith & Nephew in a research report on Monday, November 6th. Deutsche Bank increased their target price on shares of Smith & Nephew from GBX 1,200 ($16.15) to GBX 1,315 ($17.70) and gave the stock a “hold” rating in a research report on Monday, October 23rd. Finally, Citigroup reiterated a “sell” rating and set a GBX 1,160 ($15.61) target price on shares of Smith & Nephew in a research report on Thursday, October 12th.
Shares of Smith & Nephew (LON:SN) opened at GBX 1,291 ($17.38) on Monday. Smith & Nephew has a fifty-two week low of GBX 1,143 ($15.38) and a fifty-two week high of GBX 1,442 ($19.41).
COPYRIGHT VIOLATION NOTICE: “Smith & Nephew plc (SN) Receives Average Rating of “Hold” from Analysts” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://transcriptdaily.com/2017/12/18/smith-nephew-plc-sn-receives-average-rating-of-hold-from-analysts.html.
Smith & Nephew Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.